A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso(R) (Treprostinil) Inhalation Solution

Trial Profile

A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso(R) (Treprostinil) Inhalation Solution

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Treprostinil (Primary) ; Epoprostenol; Epoprostenol agonists; Treprostinil; Treprostinil; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms ASPIRE
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 24 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top